Add time:08/31/2019         Source:sciencedirect.com

Impulse control disorders (ICD) are increasingly recognized in patients with Parkinson’s disease (PD), particularly when treated with commonly used dopamine agonists such as pramipexole and ropinirole [1], [2], [3], [4], [5]. Less evident is the possible association between monoamine oxidase inhibitors type B (MAO-B) and the development of ICD [5]. Rasagiline is a second generation MAO-B I inducing moderate symptomatic and possibly disease modifying benefits with apparently good tolerability and safety profile in PD patients. Rasagiline is effective and well tolerated in PD as a monotherapy or in combination with levodopa [6]. Here, we report a patient with PD who developed ICD when treated de novo with MAO-B inhibitors.

We also recommend Trading Suppliers and Manufacturers of Rasagiline (cas 136236-51-6). Pls Click Website Link as below: cas 136236-51-6 suppliers